AXT Inc vs Lemonade Inc — how do they compare? AXT Inc trades at $57.51 (market cap $3.77B), while Lemonade Inc trades at $70.3 (market cap $5.39B). The key difference: Lemonade Inc is the larger of the two by market cap, and Lemonade Inc is trading nearer its 52-week high, AXT Inc nearer its low. Which is the better fit depends on your goals.
| AXTI | LMND | |
|---|---|---|
Market Cap | $3.77B | $5.39B |
Sector | Technology | Financials |
52-Week High | $140.83 | $96.57 |
52-Week Low | $1.92 | $36.28 |
Enterprise Value | $3.73B | $5.21B |
Signals from Pluang's Aura AI — not financial advice
AXTI trades at $50.46, down 11.8% in the past 24 hours, reflecting bearish technical signals and negative profitability metrics. The company reported a net loss of $21.26M in 2025 despite revenue of $88.33M, though 2026 projections show improved margins. Recent news highlights strong AI-driven demand for indium phosphide substrates and a $100M+ backlog, but export delays and cash flow risks remain concerns. Analyst consensus is bullish with 7 buy ratings, but technical indicators suggest near-term pressure.
The stock faces near-term headwinds from weak cash flow and high valuations (P/S 27.84), but long-term growth potential exists if AI demand materializes and capacity expansion executes smoothly. Key risks include geopolitical tensions affecting exports and execution challenges in scaling production. Investors should weigh the bullish analyst outlook against persistent fundamental weaknesses and technical bearishness.
Lemonade (LMND) trades at $70.62, up 0.16% on the day, with a bullish technical signal from moving averages and ADX indicators. Revenue growth is robust, increasing from $257M in 2022 to $738M in 2025, while net losses are narrowing, with the net margin improving from -116.02% to -22.43% over the same period. Recent news highlights expansion into new states and a renegotiated reinsurance program, improving cost structure and capital efficiency.
The outlook is mixed; strong revenue growth and narrowing losses present a long-term opportunity, but the stock trades above the consensus price target of $67.00, with 40% of analysts rating it a sell. Key risks include persistent unprofitability, high valuation multiples, and execution challenges in scaling the AI-driven insurance model. Positive cash flow from operations is projected for 2026, a potential inflection point.
Trailing returns across standard periods
Latest headlines on both assets
AXT develops and manufactures high-performance compound semiconductor wafer substrates. Its products, like indium phosphide and gallium arsenide, are essential for data centers, 5G, and consumer electronics.
Read more on AXTI →Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →